Upcoming Events   2010   2009   2008   2007   2006   2005   2004  
  Home > News & Events > 2008  
   2008 NEWS ARCHIVE
 
METABOLEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF MBX-8025
November 18, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025.
    More >
 
METABOLEX ANNOUNCES POSITIVE RESULTS FROM PHASE 1a CLINICAL TRIAL OF MBX-2982
November 12, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982.
    More >
 
TWO METABOLEX PROJECTS RECOGNIZED IN WINDHOVER’S TOP 10 LISTS FOR PARTNERING OPPORTUNITIES
November 3, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover’s “Top 10 most interesting projects available for partnering” in their respective categories.
    More >
 
METABOLEX ANNOUNCES ELECTION OF ROBERT L. ZERBE TO BOARD OF DIRECTORS
September 30, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Robert L. Zerbe, M.D., has been elected to its Board of Directors.
    More >
 
METABOLEX NAMES ZHAO, MARTIN TO EXECUTIVE POSTS
July 7, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has promoted Zuchun ‘Spring’ Zhao to Vice President of Chemical Sciences, and Robert Martin to Vice President of Project and Portfolio Management.
    More >
 
METABOLEX COMPLETES PATIENT ENROLLMENT IN PHASE 2 TRIAL OF MBX-8025 FOR TREATMENT OF DYSLIPIDEMIA
June 16, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.
    More >
 
METABOLEX APPOINTS DONALD HILL AS CHIEF FINANCIAL OFFICER
April 14, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions...
    More >
 
METABOLEX INITIATES PHASE 1 TRIAL OF MBX-2982
March 26, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has dosed the first cohort of healthy subjects in a Phase 1 clinical trial of MBX-2982, a potential first-in-class treatment for type 2 diabetes ...
    More >
 
   2008 EVENTS
 
  Piper Jaffray 20th Annual Health Care Conference
The New York Palace, New York, NY; December 2-3, 2008
  Windhover’s Therapeutic Area Partnerships
Loews Hotel, Philadelphia, PA; November 3-5, 2008
  2nd World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy)
Catalonia Palace of Congresses, Barcelona, Spain; October 30-November 2, 2008
  BIO Investor Forum
Palace Hotel, San Francisco, CA; October 29-31, 2008
  BIO International Convention
San Diego Convention Center, San Diego, CA; June 17-20, 2008
 

Canaccord Adams Diabetes & Obesity Conference
Hotel Nikko, San Francisco, CA; June 6, 2008